Xtl Biopharmaceuticals (XTLB) Interest Expenses (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Interest Expenses of $284000.0 for Q4 2024, up 405.38% on a QoQ basis from -$93000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Interest Expenses (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Interest Expenses for 13 consecutive years, with $284000.0 the latest figure, recorded in Q4 2024.
- Quarterly Interest Expenses changed N/A year-over-year to $284000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $191000.0 (up 17.9% YoY) and the FY2025 annual result came in at $266000.0, up 137.5% from the prior year.
- Interest Expenses rose to $284000.0 in Q4 2024 per XTLB's latest filing, from -$93000.0 in the prior quarter.
- Over the last five years, Interest Expenses for XTLB reached as high as $284000.0 in Q4 2024 and fell as low as -$93000.0 in Q3 2024.
- A 3-year average of $5500.0 and a median of -$14500.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses sank 1300.0% — and 2024, when it surged 59.38%.
- Year by year, Interest Expenses stood at -$2000.0 in 2022, then plunged by 1300.0% to -$28000.0 in 2023, then jumped by 1114.29% to $284000.0 in 2024.
- According to Business Quant data, Interest Expenses over the past three periods registered $284000.0, -$93000.0, and -$13000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 284,000.00 |
| Dec 31, 2024 | 284,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Jun 30, 2024 | -13,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Mar 31, 2024 | -16,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Sep 30, 2023 | -28,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Jun 30, 2023 | -32,000.00 |
| Mar 31, 2023 | -25,000.00 |
| Mar 31, 2023 | -25,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Jun 30, 2022 | -11,000.00 |
| Jun 30, 2022 | -11,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Mar 31, 2022 | -9,000.00 |